Osimertinib: A potential new standard of care for advanced EGFR-mutated NSCLC | Suresh Ramalingam

preview_player
Показать описание
Lead investigator Suresh Ramalingam discusses the practice-changing results of the FLAURA study pitting osimertinib against gefitinib or erlotinib in the first-line advanced NSCLC setting.

*Originally published on Medicine Matters oncology on September 15, 2017*
  1. Medicine Matters oncology
  2. Medicine
  3. Oncology
  4. Cancer
  5. ESMO 2017
  6. Suresh Ramalingam
Рекомендации по теме
Osimertinib: A potential 0:06:50

Osimertinib: A potential new standard of care for advanced EGFR-mutated NSCLC | Suresh Ramalingam

15 Years of 0:58:47

15 Years of Advances in EGFR Mutant Lung Cancer

Dr. Ramalingam on 0:01:40

Dr. Ramalingam on the Role of Osimertinib in eGFR T790M-Positive Advanced NSCLC

Osimertinib resistance in 0:01:41

Osimertinib resistance in non-small cell lung cancer: Pathways and potential solutions

Osimertinib, the Standard 0:06:06

Osimertinib, the Standard for EGFR+ NSCLC

Post-Osimertinib Treatment Options 0:02:43

Post-Osimertinib Treatment Options for EGFR+ NSCLC - Targeted Therapies in Lung Cancer 2023

New Standard for 0:05:14

New Standard for Treating Stage 4 EGFR+ NSCLC

Global Perspectives on 0:08:55

Global Perspectives on Use of Osimertinib in EGFR+ NSCLC

Osimertinib plus chemotherapy 0:03:22

Osimertinib plus chemotherapy shows superior results versus osimertinib alone for EGFR-mutated a...

Osimertinib For Uncommon 0:03:30

Osimertinib For Uncommon EGFR Mutations in NSCLC

Osimertinib’s Role in 0:06:22

Osimertinib’s Role in EGFR+ Metastatic Lung Cancer

2020 TTF EGFR 0:07:24

2020 TTF EGFR SESSION QA PANEL Does Progression Always Occur on Osimertinib (Tagrisso)?

Case 2: Osimertinib 0:03:09

Case 2: Osimertinib in EGFR-Mutated Lung Cancer

Osimertinib for EGFR-mutant 0:00:55

Osimertinib for EGFR-mutant lung cancer

New agents for 0:04:38

New agents for EGFR+ NSCLC: osimertinib and beyond

Is adjuvant chemotherapy 0:03:52

Is adjuvant chemotherapy in EGFR mutated NSCLC still required?

Dr. Goldberg Discusses 0:01:52

Dr. Goldberg Discusses Osimertinib in NSCLC

Case 4: Metastatic 0:06:41

Case 4: Metastatic EGFR+ NSCLC Progressing on Osimertinib

Osimertinib + ipilimumab 0:02:21

Osimertinib + ipilimumab in EGFR-mutated NSCLC

Osimertinib suitable for 0:03:31

Osimertinib suitable for first line EGFRm lung cancer

Dr. Padda on 0:01:43

Dr. Padda on Overcoming Resistance to Osimertinib in EGFR+ NSCLC

Lung Cancer can 0:00:53

Lung Cancer can now be treated by a Tablet called Osimertinib, Tagrisso. Part 2 #cancer

Osimertinib for Treatment 0:01:02

Osimertinib for Treatment of EGFR+ Lung Cancer

Understanding, preventing, and 0:20:18

Understanding, preventing, and delaying EGFR resistance in the era of Osimertinib